{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-22-000035","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.823036+00:00","generated_at":"2026-06-24T02:43:27.522455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)","bullets":["Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.","Gross margin 86% vs 89% YoY; operating loss $17.9M vs $13.0M.","Net loss $18.5M ($0.54 per diluted share) vs $14.0M ($0.42) in Q2 2021.","Cash $114.4M; long-term borrowings $35.1M; FY2022 revenue guidance reaffirmed at $106-108M.","FDA clearances for iFuse-TORQ pelvic fractures and iFuse Bedrock Granite; CMS NTAP up to $9,828."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-22-000035","json":"https://secwatch.observer/filing/0001459839-22-000035.json","markdown":"https://secwatch.observer/filing/0001459839-22-000035.md","text":"https://secwatch.observer/filing/0001459839-22-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/0001459839-22-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/sibn-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:43:27.522455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}